OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
Rhea-AI Summary
OraSure (NASDAQ: OSUR) will report fourth quarter 2025 financial results and host an earnings conference call on February 25, 2026 at 5:00 PM ET. A live webcast will be available via the company's investor relations page and will be archived after the call.
Investors are asked to register and access the webcast at least 10 minutes before the start time.
Positive
- None.
Negative
- None.
News Market Reaction – OSUR
On the day this news was published, OSUR gained 4.06%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $202M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OSUR slipped 0.73% while peers were mixed: STSS up 6.45%, INFU up 2.39%, NYXH and UTMD modestly down. This points to stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Board nominations | Neutral | +1.7% | Altai Capital nominates two directors amid concerns over share performance and strategy. |
| Jan 5 | Regulatory submission | Positive | +3.8% | FDA submissions for CT/NG molecular self-test and Colli-Pee™ STI collection device. |
| Dec 17 | Activist response | Neutral | +1.6% | Company responds to Altai, emphasizing <b>$216M</b> cash, no debt, buyback authorization. |
| Dec 17 | Activist intentions | Neutral | +1.6% | Altai signals plan to nominate directors seeking governance and strategic changes. |
| Nov 17 | Investor conference | Neutral | -2.6% | Participation in Stephens conference with a webcasted Q&A session for investors. |
Recent headlines, including activist activity and product submissions, mostly saw modest positive price reactions, with only a conference appearance drawing a small decline.
Over the last few months, OraSure faced activist pressure from Altai Capital, which disclosed stakes around 5% and pursued board nominations on Dec 17, 2025 and Jan 15, 2026. The company highlighted a strong cash position of $216M and a $40M repurchase authorization while reporting lower Q3 sales and wider losses. In early Jan 2026, OraSure submitted CT/NG self-test and Colli-Pee™ devices for FDA review. The new earnings-date announcement follows this backdrop of strategic shifts, clinical progress, and governance engagement.
Market Pulse Summary
This announcement sets the timing for OraSure’s Q4 2025 earnings call, which will update investors after Q3 results showed $27.085M in revenue and an operating loss of $16.1M, alongside continued activist scrutiny. The call may address trends behind prior 32% and 41% revenue declines and provide insight into CT/NG test and Colli-Pee™ progress, BioMedomics integration, and capital allocation. Investors may watch for clarity on margin trajectory and cash deployment from the $216.478M balance.
AI-generated analysis. Not financial advice.
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com
| Investor Contact: Jason Plagman VP, Investor Relations investorinfo@orasure.com | Media Contact: Amy Koch Director, Corporate Communications media@orasure.com |
FAQ
When is OraSure (OSUR) announcing Q4 2025 results and holding the earnings call?
How can investors access the OraSure (OSUR) Q4 2025 webcast and registration?
Will the OraSure (OSUR) Q4 2025 webcast be available after the live call?
What will OraSure (OSUR) discuss during the February 25, 2026 earnings call?
When should attendees join the OraSure (OSUR) webcast on February 25, 2026?
